BioXcel Therapeutics Ownership 2024 | Who Owns BioXcel Therapeutics Now?
Institutional Ownership
31.63%
Insider Ownership
20.06%
Retail Ownership
48.31%
Institutional Holders
74.00
BioXcel Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC | 9.68% | 0.05% | 2,987,000 | 2,616,027 | 705.18% | 3,823,360 | Jun 30, 2024 |
FMR LLC | 7.14% | 0.00% | 2,205,172 | -288,944 | -11.59% | 2,822,621 | Jun 30, 2024 |
VANGUARD GROUP INC | 3.14% | - | 970,430 | -128,945 | -11.73% | 1,242,151 | Jun 30, 2024 |
BLACKROCK INC. | 1.43% | - | 440,685 | -887,376 | -66.82% | 564,077 | Jun 30, 2024 |
BNP PARIBAS ARBITRAGE, SNC | 0.88% | 0.00% | 273,135 | 251,385 | 1155.79% | 349,613 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.86% | - | 266,719 | -191,201 | -41.75% | 341,470 | Jun 30, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.66% | - | 203,615 | 12,645 | 6.62% | 260,627 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.63% | - | 194,953 | -16,649 | -7.87% | 249,540,000 | Jun 30, 2024 |
WELLS FARGO & COMPANY/MN | 0.43% | - | 133,676 | 10,590 | 8.60% | 171,105 | Jun 30, 2024 |
STATE STREET CORP | 0.40% | - | 124,749 | -340,159 | -73.17% | 159,679,000 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.40% | 0.00% | 122,752 | 77,628 | 172.03% | 157,123 | Jun 30, 2024 |
MORGAN STANLEY | 0.38% | - | 116,563 | -105,736 | -47.56% | 149,200 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.32% | - | 98,967 | 76,197 | 334.64% | 126,677 | Jun 30, 2024 |
PENNANT INVESTORS, LP | 0.27% | 0.03% | 83,900 | - | - | 107,392 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.24% | 0.01% | 74,922 | 74,922 | 100.00% | 95,900 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.24% | - | 73,426 | 26,058 | 55.01% | 93,985 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.19% | 0.01% | 57,338 | 43,348 | 309.85% | 73,000 | Jun 30, 2024 |
HRT FINANCIAL LP | 0.17% | 0.00% | 53,010 | 53,010 | 100.00% | 67,000 | Jun 30, 2024 |
UBS GROUP AG | 0.17% | - | 52,483 | -94,674 | -64.34% | 67,177 | Jun 30, 2024 |
FEDERATED HERMES, INC. | 0.16% | 0.00% | 50,251 | 2,344 | 4.89% | 64,321,000 | Jun 30, 2024 |
BioXcel Therapeutics's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 9.68% of the company's total share outstanding, currently valued at $3.82M. The top 10 institutional shareholders own together 25.27% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC | 9.68% | 0.05% | 2,987,000 | 2,616,027 | 705.18% | 3,823,360 | Jun 30, 2024 |
ROSALIND ADVISORS, INC. | 0.13% | 0.04% | 39,672 | 39,672 | 100.00% | 50,780 | Jun 30, 2024 |
PENNANT INVESTORS, LP | 0.27% | 0.03% | 83,900 | - | - | 107,392 | Jun 30, 2024 |
GROUND SWELL CAPITAL, LLC | 0.04% | 0.01% | 11,000 | 11,000 | 100.00% | 14,080 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.10% | 0.01% | 30,295 | 30,295 | 100.00% | 38,778 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.24% | 0.01% | 74,922 | 74,922 | 100.00% | 95,900 | Jun 30, 2024 |
REDWOOD WEALTH MANAGEMENT GROUP, LLC | 0.02% | 0.01% | 5,380 | 5,380 | 100.00% | 6,886 | Jun 30, 2024 |
XTX TOPCO LTD | 0.15% | 0.01% | 46,503 | 15,291 | 48.99% | 59,524 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.19% | 0.01% | 57,338 | 43,348 | 309.85% | 73,000 | Jun 30, 2024 |
ARETE WEALTH ADVISORS, LLC | 0.14% | 0.00% | 43,500 | 43,500 | 100.00% | 56,000 | Jun 30, 2024 |
0.13% | 0.00% | 40,000 | 40,000 | 100.00% | 36,804 | Jun 30, 2024 | |
ALLSQUARE WEALTH MANAGEMENT LLC | 0.01% | 0.00% | 4,527 | - | - | 5,795 | Jun 30, 2024 |
HENNION & WALSH ASSET MANAGEMENT, INC. | 0.13% | 0.00% | 40,599 | 3,197 | 8.55% | 51,967 | Jun 30, 2024 |
CAPITAL INVESTMENT ADVISORY SERVICES, LLC | 0.06% | 0.00% | 17,725 | -100 | -0.56% | 22,688 | Jun 30, 2024 |
SEACREST WEALTH MANAGEMENT, LLC | 0.05% | 0.00% | 15,750 | -1,500 | -8.70% | 20,160 | Jun 30, 2024 |
TOCQUEVILLE ASSET MANAGEMENT L.P. | 0.14% | 0.00% | 43,750 | -4,500 | -9.33% | 56,000 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 23,050 | 23,050 | 100.00% | 29,504 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.12% | 0.00% | 37,400 | 37,400 | 100.00% | 47,872 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.05% | 0.00% | 15,403 | 15,403 | 100.00% | 19,716 | Jun 30, 2024 |
APOLLON WEALTH MANAGEMENT, LLC | 0.03% | 0.00% | 10,420 | 250 | 2.46% | 13,338 | Jun 30, 2024 |
The largest BioXcel Therapeutics shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 2.99M shares of BioXcel Therapeutics (BTAI), representing 0.05% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC | 9.68% | 0.05% | 2,987,000 | 2,616,027 | 705.18% | 3,823,360 | Jun 30, 2024 |
BNP PARIBAS ARBITRAGE, SNC | 0.88% | 0.00% | 273,135 | 251,385 | 1155.79% | 349,613 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.40% | 0.00% | 122,752 | 77,628 | 172.03% | 157,123 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.32% | - | 98,967 | 76,197 | 334.64% | 126,677 | Jun 30, 2024 |
Y-INTERCEPT (HONG KONG) LTD | 0.24% | 0.01% | 74,922 | 74,922 | 100.00% | 95,900 | Jun 30, 2024 |
HRT FINANCIAL LP | 0.17% | 0.00% | 53,010 | 53,010 | 100.00% | 67,000 | Jun 30, 2024 |
ARETE WEALTH ADVISORS, LLC | 0.14% | 0.00% | 43,500 | 43,500 | 100.00% | 56,000 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.19% | 0.01% | 57,338 | 43,348 | 309.85% | 73,000 | Jun 30, 2024 |
0.13% | 0.00% | 40,000 | 40,000 | 100.00% | 36,804 | Jun 30, 2024 | |
ROSALIND ADVISORS, INC. | 0.13% | 0.04% | 39,672 | 39,672 | 100.00% | 50,780 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.12% | 0.00% | 37,400 | 37,400 | 100.00% | 47,872 | Jun 30, 2024 |
SQUAREPOINT OPS LLC | 0.11% | 0.00% | 34,257 | 34,257 | 100.00% | 43,849 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.10% | 0.01% | 30,295 | 30,295 | 100.00% | 38,778 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.24% | - | 73,426 | 26,058 | 55.01% | 93,985 | Jun 30, 2024 |
COMMONWEALTH EQUITY SERVICES, LLC | 0.08% | 0.00% | 25,400 | 25,400 | 100.00% | 33,000 | Jun 30, 2024 |
VERITION FUND MANAGEMENT LLC | 0.08% | 0.00% | 25,155 | 25,155 | 100.00% | 32,198 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 23,050 | 23,050 | 100.00% | 29,504 | Jun 30, 2024 |
LPL FINANCIAL LLC | 0.06% | - | 18,402 | 18,402 | 100.00% | 23,555 | Jun 30, 2024 |
SIMPLEX TRADING, LLC | 0.10% | - | 32,292 | 17,971 | 125.49% | 41,000 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.05% | 0.00% | 15,403 | 15,403 | 100.00% | 19,716 | Jun 30, 2024 |
As of Jun 30 2024, BioXcel Therapeutics's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 2.62M stocks of BTAI, valued at $3.82M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLACKROCK INC. | 1.43% | - | 440,685 | -887,376 | -66.82% | 564,077 | Jun 30, 2024 |
AMERIPRISE FINANCIAL INC | - | - | - | -579,164 | -100.00% | - | Jun 30, 2024 |
STATE STREET CORP | 0.40% | - | 124,749 | -340,159 | -73.17% | 159,679,000 | Jun 30, 2024 |
BEACON POINTE ADVISORS, LLC | - | - | - | -301,735 | -100.00% | - | Jun 30, 2024 |
FMR LLC | 7.14% | 0.00% | 2,205,172 | -288,944 | -11.59% | 2,822,621 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 0.86% | - | 266,719 | -191,201 | -41.75% | 341,470 | Jun 30, 2024 |
VANGUARD GROUP INC | 3.14% | - | 970,430 | -128,945 | -11.73% | 1,242,151 | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | - | - | - | -123,077 | -100.00% | - | Jun 30, 2024 |
MORGAN STANLEY | 0.38% | - | 116,563 | -105,736 | -47.56% | 149,200 | Jun 30, 2024 |
CASTLEVIEW PARTNERS, LLC | - | - | - | -97,279 | -100.00% | - | Jun 30, 2024 |
UBS GROUP AG | 0.17% | - | 52,483 | -94,674 | -64.34% | 67,177 | Jun 30, 2024 |
ALLIANCEBERNSTEIN L.P. | - | - | - | -29,990 | -100.00% | - | Jun 30, 2024 |
ATOM INVESTORS LP | - | - | - | -29,816 | -100.00% | - | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -23,707 | -100.00% | - | Jun 30, 2024 |
INVESCO LTD. | - | - | - | -18,841 | -100.00% | - | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.04% | - | 11,502 | -18,183 | -61.25% | 14,721 | Jun 30, 2024 |
DEUTSCHE BANK AG\ | - | - | - | -17,537 | -100.00% | - | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.63% | - | 194,953 | -16,649 | -7.87% | 249,540,000 | Jun 30, 2024 |
BARCLAYS PLC | - | - | - | -14,772 | -100.00% | - | Jun 30, 2024 |
DAVENPORT & CO LLC | 0.07% | 0.00% | 21,205 | -13,180 | -38.33% | 27,142 | Jun 30, 2024 |
As of Jun 30 2024, BioXcel Therapeutics's biggest institutional seller is BLACKROCK INC.. The company sold -0.89M shares of BTAI, valued at $564.08K.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
Y-INTERCEPT (HONG KONG) LTD | 0.24% | 0.01% | 74,922 | 74,922 | 100.00% | 95,900 | Jun 30, 2024 |
HRT FINANCIAL LP | 0.17% | 0.00% | 53,010 | 53,010 | 100.00% | 67,000 | Jun 30, 2024 |
0.13% | 0.00% | 40,000 | 40,000 | 100.00% | 36,804 | Jun 30, 2024 | |
ROSALIND ADVISORS, INC. | 0.13% | 0.04% | 39,672 | 39,672 | 100.00% | 50,780 | Jun 30, 2024 |
CENTIVA CAPITAL, LP | 0.12% | 0.00% | 37,400 | 37,400 | 100.00% | 47,872 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.10% | 0.01% | 30,295 | 30,295 | 100.00% | 38,778 | Jun 30, 2024 |
COMMONWEALTH EQUITY SERVICES, LLC | 0.08% | 0.00% | 25,400 | 25,400 | 100.00% | 33,000 | Jun 30, 2024 |
VERITION FUND MANAGEMENT LLC | 0.08% | 0.00% | 25,155 | 25,155 | 100.00% | 32,198 | Jun 30, 2024 |
PALOMA PARTNERS MANAGEMENT CO | 0.07% | 0.00% | 23,050 | 23,050 | 100.00% | 29,504 | Jun 30, 2024 |
LPL FINANCIAL LLC | 0.06% | - | 18,402 | 18,402 | 100.00% | 23,555 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.05% | 0.00% | 15,403 | 15,403 | 100.00% | 19,716 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.05% | 0.00% | 15,100 | 15,100 | 100.00% | 19,328 | Jun 30, 2024 |
AQR CAPITAL MANAGEMENT LLC | 0.05% | - | 14,360 | 14,360 | 100.00% | 18,381 | Jun 30, 2024 |
MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | - | 11,389 | 11,389 | 100.00% | 14,578 | Jun 30, 2024 |
GROUND SWELL CAPITAL, LLC | 0.04% | 0.01% | 11,000 | 11,000 | 100.00% | 14,080 | Jun 30, 2024 |
REDWOOD WEALTH MANAGEMENT GROUP, LLC | 0.02% | 0.01% | 5,380 | 5,380 | 100.00% | 6,886 | Jun 30, 2024 |
MACQUARIE GROUP LTD | 0.00% | - | 1,053 | 1,053 | 100.00% | 1,348 | Jun 30, 2024 |
CWM, LLC | 0.00% | - | 850 | 850 | 100.00% | 1,000 | Jun 30, 2024 |
BioXcel Therapeutics's largest new institutional shareholder by number of shares is Y-INTERCEPT (HONG KONG) LTD, purchased 74.92K shares, valued at $95.90K, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
AMERIPRISE FINANCIAL INC | - | - | - | -579,164 | -100.00% | - | Jun 30, 2024 |
BEACON POINTE ADVISORS, LLC | - | - | - | -301,735 | -100.00% | - | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | - | - | - | -123,077 | -100.00% | - | Jun 30, 2024 |
CASTLEVIEW PARTNERS, LLC | - | - | - | -97,279 | -100.00% | - | Jun 30, 2024 |
ALLIANCEBERNSTEIN L.P. | - | - | - | -29,990 | -100.00% | - | Jun 30, 2024 |
ATOM INVESTORS LP | - | - | - | -29,816 | -100.00% | - | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -23,707 | -100.00% | - | Jun 30, 2024 |
INVESCO LTD. | - | - | - | -18,841 | -100.00% | - | Jun 30, 2024 |
DEUTSCHE BANK AG\ | - | - | - | -17,537 | -100.00% | - | Jun 30, 2024 |
BARCLAYS PLC | - | - | - | -14,772 | -100.00% | - | Jun 30, 2024 |
AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -10,315 | -100.00% | - | Jun 30, 2024 |
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | - | - | - | -2,377 | -100.00% | - | Jun 30, 2024 |
LEGAL & GENERAL GROUP PLC | - | - | - | -2,011 | -100.00% | - | Jun 30, 2024 |
AMERITAS INVESTMENT PARTNERS, INC. | - | - | - | -1,350 | -100.00% | - | Jun 30, 2024 |
ARMSTRONG ADVISORY GROUP, INC | - | - | - | -1,000 | -100.00% | - | Jun 30, 2024 |
AMALGAMATED BANK | - | - | - | -697 | -100.00% | - | Jun 30, 2024 |
RUSSELL INVESTMENTS GROUP, LTD. | - | - | - | -344 | -100.00% | - | Jun 30, 2024 |
MASSMUTUAL TRUST CO FSB/ADV | - | - | - | -297 | -100.00% | - | Jun 30, 2024 |
NEW YORK STATE COMMON RETIREMENT FUND | - | - | - | -273 | -100.00% | - | Jun 30, 2024 |
FARTHER FINANCE ADVISORS, LLC | - | - | - | -82 | -100.00% | - | Jun 30, 2024 |
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -4 | -100.00% | - | Jun 30, 2024 |
BioXcel Therapeutics's largest sold out institutional shareholder by shares sold is AMERIPRISE FINANCIAL INC, sold -0.58M shares, valued at -, as of undefined.
BioXcel Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
HARTFORD HLS SERIES FUND II INC | 0.24% | 58,399 | - | - | Dec 31, 2023 |
FIDELITY MT VERNON STREET TRUST | 0.04% | 1,203,125 | -56,949 | -4.52% | Feb 29, 2024 |
VICTORY VARIABLE INSURANCE FUNDS | 0.03% | 16,630 | - | - | Mar 31, 2024 |
VANGUARD VALLEY FORGE FUNDS | 0.03% | 13,911 | - | - | Mar 31, 2024 |
Vericimetry Funds | 0.02% | 1,780 | - | - | Mar 31, 2024 |
ALGER FUNDS | 0.02% | 18,000 | - | - | Jan 31, 2024 |
AB CAP FUND, INC. | 0.02% | 601,794 | - | - | Jan 31, 2024 |
VICTORY PORTFOLIOS | 0.01% | 383,470 | - | - | Mar 31, 2024 |
MFS SERIES TRUST I | 0.01% | 235,349 | - | - | Feb 29, 2024 |
VANGUARD EXPLORER FUND | 0.01% | 96,958 | - | - | Jan 31, 2024 |
QUANTITATIVE MASTER SERIES LLC | 0.01% | 33,014 | - | - | Mar 31, 2024 |
DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 2,978 | - | - | Mar 31, 2024 |
STEWARD FUNDS, INC. | 0.00% | 12,000 | - | - | Jan 31, 2024 |
FORUM FUNDS | 0.00% | 10,265 | - | - | Jan 31, 2024 |
DRIEHAUS MUTUAL FUNDS | 0.00% | 38,587 | - | - | Mar 28, 2024 |
IndexIQ ETF Trust | 0.00% | 9,785 | - | - | Jan 31, 2024 |
FIDELITY SELECT PORTFOLIOS | 0.00% | 274,527 | - | - | Feb 29, 2024 |
Federated Hermes MDT Series | 0.00% | 9,747 | -22,990 | -70.23% | Jan 31, 2024 |
MFS VARIABLE INSURANCE TRUST | 0.00% | 119,850 | - | - | Mar 31, 2024 |
ETFis Series Trust I | 0.00% | 4,646 | - | - | Jan 31, 2024 |
Bernstein Fund Inc | 0.00% | 26,468 | - | - | Mar 31, 2024 |
Nushares ETF Trust | 0.00% | 21,606 | - | - | Jan 31, 2024 |
AB VARIABLE PRODUCTS SERIES FUND, INC. | 0.00% | 13,062 | - | - | Mar 31, 2024 |
VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 136,670 | - | - | Mar 31, 2024 |
Humankind Benefit Corp | 0.00% | 58 | - | - | Dec 31, 2023 |
FIDELITY COMMONWEALTH TRUST | 0.00% | 7,458 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 933,567 | -293,322 | -23.91% | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 71,693 | 27,841 | 63.49% | Jan 31, 2024 |
BNY Mellon Strategic Funds, Inc. | 0.00% | 3,695 | - | - | Mar 31, 2024 |
Fidelity Commonwealth Trust II | 0.00% | 10,726 | - | - | Aug 31, 2023 |
TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 343 | - | - | Mar 31, 2024 |
ALPS ETF Trust | 0.00% | 18,588 | - | - | Feb 29, 2024 |
INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 111,957 | - | - | Jan 31, 2024 |
CLEARWATER INVESTMENT TRUST | 0.00% | 12,844 | 12,844 | - | Mar 28, 2024 |
Direxion Shares ETF Trust | 0.00% | 191,396 | - | - | Jan 31, 2024 |
HARTFORD SERIES FUND INC | 0.00% | 43,560 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 202,473 | 12,780 | 6.74% | Feb 29, 2024 |
HC CAPITAL TRUST | 0.00% | 29,713 | - | - | Mar 31, 2024 |
FIDELITY SECURITIES FUND | 0.00% | 72,720 | - | - | Jan 31, 2024 |
MML SERIES INVESTMENT FUND | 0.00% | 7,197 | - | - | Dec 31, 2023 |
OHIO NATIONAL FUND INC | 0.00% | 12,580 | - | - | Mar 31, 2024 |
Meeder Funds | 0.00% | 2,779 | - | - | Mar 31, 2024 |
GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 2,321 | - | - | Mar 31, 2024 |
MAINSTAY FUNDS TRUST | 0.00% | 114,420 | - | - | Jan 31, 2024 |
FIDELITY COVINGTON TRUST | 0.00% | 9,892 | - | - | Jan 31, 2024 |
Calvert Variable Products, Inc. | 0.00% | 1,350 | - | - | Mar 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 15,053 | - | - | Mar 31, 2024 |
NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 50,517 | - | - | Mar 31, 2024 |
MAINSTAY VP FUNDS TRUST | 0.00% | 58,416 | - | - | Mar 31, 2024 |
VANGUARD HORIZON FUNDS | 0.00% | 9,676 | - | - | Mar 31, 2024 |
AMG FUNDS III | 0.00% | 2,032 | - | - | Mar 28, 2024 |
Principal Exchange-Traded Funds | 0.00% | 3,777 | -585 | -13.41% | Mar 31, 2024 |
VANGUARD WORLD FUND | 0.00% | 63,486 | - | - | Feb 29, 2024 |
JOHN HANCOCK INVESTMENT TRUST | 0.00% | 21,620 | - | - | Mar 31, 2024 |
COLUMBIA FUNDS VARIABLE INSURANCE TRUST | 0.00% | 136,664 | -3,700 | -2.64% | Mar 31, 2024 |
HARTFORD MUTUAL FUNDS II INC | 0.00% | 38,079 | - | - | Jan 31, 2024 |
Brinker Capital Destinations Trust | 0.00% | 14,034 | - | - | Feb 29, 2024 |
SCHWAB STRATEGIC TRUST | 0.00% | 118,941 | 3,914 | 3.40% | Feb 29, 2024 |
SSGA FUNDS | 0.00% | 88 | - | - | Feb 29, 2024 |
SunAmerica Specialty Series | 0.00% | 97 | - | - | Apr 30, 2021 |
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 871 | - | - | Mar 31, 2024 |
NORTHERN FUNDS | 0.00% | 22,823 | -1,804 | -7.33% | Mar 28, 2024 |
Trust for Advised Portfolios | 0.00% | 2,915 | - | - | Dec 31, 2023 |
THRIVENT SERIES FUND INC | 0.00% | 13,669 | - | - | Mar 28, 2024 |
TIAA-CREF LIFE FUNDS | 0.00% | 301 | - | - | Mar 31, 2024 |
Victory Portfolios II | 0.00% | 5,386 | - | - | Mar 31, 2024 |
Series Portfolios Trust | 0.00% | 622 | - | - | Jan 31, 2024 |
STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 5,512 | - | - | Mar 31, 2024 |
VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 994 | - | - | Mar 31, 2024 |
COLUMBIA FUNDS SERIES TRUST I | 0.00% | 353,226 | 6,400 | 1.85% | Jan 31, 2024 |
FLEXSHARES TRUST | 0.00% | 5,766 | - | - | Jan 31, 2024 |
Dimensional ETF Trust | 0.00% | 31,326 | - | - | Jan 31, 2024 |
GPS Funds I | 0.00% | 380 | - | - | Mar 31, 2024 |
Voya VARIABLE PORTFOLIOS INC | 0.00% | 2,197 | -1,948 | -47.00% | Mar 31, 2024 |
THRIVENT MUTUAL FUNDS | 0.00% | 6,358 | - | - | Mar 28, 2024 |
Federated Hermes Global Allocation Fund | 0.00% | 624 | - | - | Feb 29, 2024 |
RBB FUND, INC. | 0.00% | 6,019 | - | - | Feb 29, 2024 |
T. Rowe Price Index Trust, Inc. | 0.00% | 1,430 | 475 | 49.74% | Mar 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 66,044 | - | - | Mar 31, 2024 |
VANGUARD WELLINGTON FUND | 0.00% | 19,926 | - | - | Feb 29, 2024 |
Goldman Sachs ETF Trust | 0.00% | 4,666 | - | - | Feb 29, 2024 |
VANGUARD SCOTTSDALE FUNDS | 0.00% | 93,615 | 11,876 | 14.53% | Feb 29, 2024 |
SPDR SERIES TRUST | 0.00% | 1,705,815 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 725,070 | -40,817 | -5.33% | Mar 31, 2024 |
RYDEX SERIES FUNDS | 0.00% | 175 | - | - | Dec 31, 2023 |
RUSSELL INVESTMENT CO | 0.00% | 10,558 | - | - | Jan 31, 2024 |
Pacer Funds Trust | 0.00% | 1,486 | - | - | Jan 31, 2024 |
MFS SERIES TRUST XV | 0.00% | 690 | - | - | Jan 31, 2024 |
WisdomTree Trust | 0.00% | 62,478 | - | - | Feb 29, 2024 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 8,720 | 8,539 | 4717.68% | Feb 29, 2024 |
VALIC Co I | 0.00% | 7,785 | -32 | -0.41% | Feb 29, 2024 |
ALLSPRING MASTER TRUST | 0.00% | 1,640 | - | - | Feb 29, 2024 |
MASSMUTUAL SELECT FUNDS | 0.00% | 23,680 | - | - | Dec 31, 2023 |
NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 2,888 | - | - | Mar 31, 2024 |
MASTER INVESTMENT PORTFOLIO | 0.00% | 1,925 | - | - | Mar 31, 2024 |
RYDEX DYNAMIC FUNDS | 0.00% | 87 | - | - | Dec 31, 2023 |
AMERICAN CENTURY ETF TRUST | 0.00% | 2,367 | - | - | Feb 29, 2024 |
PENN SERIES FUNDS INC | 0.00% | 600 | - | - | Mar 28, 2024 |
NATIONWIDE MUTUAL FUNDS | 0.00% | 2,366 | -23 | -0.96% | Jan 31, 2024 |
Guggenheim Active Allocation Fund | 0.00% | 102 | - | - | Feb 29, 2024 |
BioXcel Therapeutics's largest mutual fund holder by % of total assets is "HARTFORD HLS SERIES FUND II INC", owning 58.40K shares, compromising 0.24% of its total assets.
BioXcel Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 74 | -3.90% |
31 Mar, 24 | 77 | - |
31 Dec, 23 | 77 | -14.44% |
30 Sep, 23 | 90 | -14.29% |
30 Jun, 23 | 105 | - |
31 Mar, 23 | 105 | 19.32% |
31 Dec, 22 | 88 | -2.22% |
30 Sep, 22 | 90 | -10.89% |
30 Jun, 22 | 101 | -1.94% |
31 Mar, 22 | 103 | 6.19% |
31 Dec, 21 | 97 | -9.35% |
30 Sep, 21 | 107 | -6.96% |
30 Jun, 21 | 115 | -10.85% |
31 Mar, 21 | 129 | 0.78% |
31 Dec, 20 | 128 | 6.67% |
30 Sep, 20 | 120 | 4.35% |
30 Jun, 20 | 115 | 51.32% |
31 Mar, 20 | 76 | 72.73% |
31 Dec, 19 | 44 | 2.33% |
30 Sep, 19 | 43 | 22.86% |
30 Jun, 19 | 35 | 75.00% |
31 Mar, 19 | 20 | 81.82% |
31 Dec, 18 | 11 | -38.89% |
30 Sep, 18 | 18 | -5.26% |
30 Jun, 18 | 19 | -13.64% |
31 Mar, 18 | 22 | - |
As of 30 Jun 24, 74 institutions are holding BioXcel Therapeutics's shares, representing a decrease of -3.90% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 9,762,496 | 5.64% |
31 Mar, 24 | 9,241,283 | -1.19% |
31 Dec, 23 | 9,352,370 | -8.29% |
30 Sep, 23 | 10,198,156 | -42.33% |
30 Jun, 23 | 17,683,694 | 1.53% |
31 Mar, 23 | 17,417,154 | 29.55% |
31 Dec, 22 | 13,444,370 | 13.30% |
30 Sep, 22 | 11,866,046 | -6.53% |
30 Jun, 22 | 12,695,095 | -3.33% |
31 Mar, 22 | 13,132,715 | -5.70% |
31 Dec, 21 | 13,927,213 | 8.96% |
30 Sep, 21 | 12,781,661 | -1.91% |
30 Jun, 21 | 13,030,189 | 18.26% |
31 Mar, 21 | 11,018,501 | -10.22% |
31 Dec, 20 | 12,272,733 | 3.25% |
30 Sep, 20 | 11,886,175 | 44.84% |
30 Jun, 20 | 8,206,580 | 36.66% |
31 Mar, 20 | 6,005,005 | 38.23% |
31 Dec, 19 | 4,344,135 | 8.02% |
30 Sep, 19 | 4,021,499 | 34.20% |
30 Jun, 19 | 2,996,600 | 19.25% |
31 Mar, 19 | 2,512,887 | 3.81% |
31 Dec, 18 | 2,420,753 | -25.57% |
30 Sep, 18 | 3,252,256 | -12.66% |
30 Jun, 18 | 3,723,565 | -20.70% |
31 Mar, 18 | 4,695,260 | - |
BioXcel Therapeutics (BTAI) has 9.76M shares outstanding as of 30 Jun 24, up 5.64% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 31.63% | 3.14% |
31 Mar, 24 | 31.73% | 3.11% |
31 Dec, 23 | 31.95% | 2.62% |
30 Sep, 23 | 34.94% | 0.91% |
30 Jun, 23 | 61.80% | 1.67% |
31 Mar, 23 | 60.87% | 2.65% |
31 Dec, 22 | 47.90% | 2.67% |
30 Sep, 22 | 42.35% | 2.06% |
30 Jun, 22 | 45.36% | 2.06% |
31 Mar, 22 | 46.94% | 1.89% |
31 Dec, 21 | 49.78% | 2.38% |
30 Sep, 21 | 45.69% | 1.68% |
30 Jun, 21 | 52.20% | 2.59% |
31 Mar, 21 | 44.93% | 1.40% |
31 Dec, 20 | 56.60% | 2.13% |
30 Sep, 20 | 51.57% | 3.15% |
30 Jun, 20 | 40.44% | 4.03% |
31 Mar, 20 | 31.66% | 4.45% |
31 Dec, 19 | 26.67% | 4.09% |
30 Sep, 19 | 25.53% | 6.98% |
30 Jun, 19 | 19.12% | 7.43% |
31 Mar, 19 | 16.04% | 6.72% |
31 Dec, 18 | 15.45% | 3.58% |
30 Sep, 18 | 20.79% | 3.67% |
30 Jun, 18 | 23.80% | 1.42% |
31 Mar, 18 | 40.98% | - |
As of 30 Jun 24, BioXcel Therapeutics is held by 31.63% institutional shareholders, representing a 3.14% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 44 | 51.72% |
31 Mar, 24 | 29 | -14.71% |
31 Dec, 23 | 34 | -15.00% |
30 Sep, 23 | 40 | -27.27% |
30 Jun, 23 | 55 | 1.85% |
31 Mar, 23 | 54 | 42.11% |
31 Dec, 22 | 38 | -5.00% |
30 Sep, 22 | 40 | -16.67% |
30 Jun, 22 | 48 | -11.11% |
31 Mar, 22 | 54 | 3.85% |
31 Dec, 21 | 52 | -13.33% |
30 Sep, 21 | 60 | -1.64% |
30 Jun, 21 | 61 | -11.59% |
31 Mar, 21 | 69 | -5.48% |
31 Dec, 20 | 73 | -2.67% |
30 Sep, 20 | 75 | -3.85% |
30 Jun, 20 | 78 | 50.00% |
31 Mar, 20 | 52 | 85.71% |
31 Dec, 19 | 28 | -9.68% |
30 Sep, 19 | 31 | 10.71% |
30 Jun, 19 | 28 | 86.67% |
31 Mar, 19 | 15 | 275.00% |
31 Dec, 18 | 4 | -60.00% |
30 Sep, 18 | 10 | - |
30 Jun, 18 | 10 | -54.55% |
31 Mar, 18 | 22 | - |
44 institutional shareholders have increased their position in BTAI stock as of 30 Jun 24 compared to 29 in the previous quarter (a 51.72% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | 18 | -28.00% |
31 Mar, 24 | 25 | -13.79% |
31 Dec, 23 | 29 | -9.38% |
30 Sep, 23 | 32 | 39.13% |
30 Jun, 23 | 23 | -17.86% |
31 Mar, 23 | 28 | - |
31 Dec, 22 | 28 | - |
30 Sep, 22 | 28 | 3.70% |
30 Jun, 22 | 27 | 3.85% |
31 Mar, 22 | 26 | 8.33% |
31 Dec, 21 | 24 | -4.00% |
30 Sep, 21 | 25 | -21.88% |
30 Jun, 21 | 32 | -3.03% |
31 Mar, 21 | 33 | 6.45% |
31 Dec, 20 | 31 | 47.62% |
30 Sep, 20 | 21 | 10.53% |
30 Jun, 20 | 19 | 5.56% |
31 Mar, 20 | 18 | 157.14% |
31 Dec, 19 | 7 | 75.00% |
30 Sep, 19 | 4 | - |
30 Jun, 19 | 4 | - |
31 Mar, 19 | 4 | -20.00% |
31 Dec, 18 | 5 | 25.00% |
30 Sep, 18 | 4 | -33.33% |
30 Jun, 18 | 6 | - |
31 Mar, 18 | - | - |
18 institutional shareholders have reduced their position in BTAI stock as of 30 Jun 24 compared to 25 in the previous quarter (a -28.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 74 | -3.90% | 9,762,496 | 5.64% | 31.63% | 3.14% | 44 | 51.72% | 18 | -28.00% |
31 Mar, 24 | 77 | - | 9,241,283 | -1.19% | 31.73% | 3.11% | 29 | -14.71% | 25 | -13.79% |
31 Dec, 23 | 77 | -14.44% | 9,352,370 | -8.29% | 31.95% | 2.62% | 34 | -15.00% | 29 | -9.38% |
30 Sep, 23 | 90 | -14.29% | 10,198,156 | -42.33% | 34.94% | 0.91% | 40 | -27.27% | 32 | 39.13% |
30 Jun, 23 | 105 | - | 17,683,694 | 1.53% | 61.80% | 1.67% | 55 | 1.85% | 23 | -17.86% |
31 Mar, 23 | 105 | 19.32% | 17,417,154 | 29.55% | 60.87% | 2.65% | 54 | 42.11% | 28 | - |
31 Dec, 22 | 88 | -2.22% | 13,444,370 | 13.30% | 47.90% | 2.67% | 38 | -5.00% | 28 | - |
30 Sep, 22 | 90 | -10.89% | 11,866,046 | -6.53% | 42.35% | 2.06% | 40 | -16.67% | 28 | 3.70% |
30 Jun, 22 | 101 | -1.94% | 12,695,095 | -3.33% | 45.36% | 2.06% | 48 | -11.11% | 27 | 3.85% |
31 Mar, 22 | 103 | 6.19% | 13,132,715 | -5.70% | 46.94% | 1.89% | 54 | 3.85% | 26 | 8.33% |
31 Dec, 21 | 97 | -9.35% | 13,927,213 | 8.96% | 49.78% | 2.38% | 52 | -13.33% | 24 | -4.00% |
30 Sep, 21 | 107 | -6.96% | 12,781,661 | -1.91% | 45.69% | 1.68% | 60 | -1.64% | 25 | -21.88% |
30 Jun, 21 | 115 | -10.85% | 13,030,189 | 18.26% | 52.20% | 2.59% | 61 | -11.59% | 32 | -3.03% |
31 Mar, 21 | 129 | 0.78% | 11,018,501 | -10.22% | 44.93% | 1.40% | 69 | -5.48% | 33 | 6.45% |
31 Dec, 20 | 128 | 6.67% | 12,272,733 | 3.25% | 56.60% | 2.13% | 73 | -2.67% | 31 | 47.62% |
30 Sep, 20 | 120 | 4.35% | 11,886,175 | 44.84% | 51.57% | 3.15% | 75 | -3.85% | 21 | 10.53% |
30 Jun, 20 | 115 | 51.32% | 8,206,580 | 36.66% | 40.44% | 4.03% | 78 | 50.00% | 19 | 5.56% |
31 Mar, 20 | 76 | 72.73% | 6,005,005 | 38.23% | 31.66% | 4.45% | 52 | 85.71% | 18 | 157.14% |
31 Dec, 19 | 44 | 2.33% | 4,344,135 | 8.02% | 26.67% | 4.09% | 28 | -9.68% | 7 | 75.00% |
30 Sep, 19 | 43 | 22.86% | 4,021,499 | 34.20% | 25.53% | 6.98% | 31 | 10.71% | 4 | - |
30 Jun, 19 | 35 | 75.00% | 2,996,600 | 19.25% | 19.12% | 7.43% | 28 | 86.67% | 4 | - |
31 Mar, 19 | 20 | 81.82% | 2,512,887 | 3.81% | 16.04% | 6.72% | 15 | 275.00% | 4 | -20.00% |
31 Dec, 18 | 11 | -38.89% | 2,420,753 | -25.57% | 15.45% | 3.58% | 4 | -60.00% | 5 | 25.00% |
30 Sep, 18 | 18 | -5.26% | 3,252,256 | -12.66% | 20.79% | 3.67% | 10 | - | 4 | -33.33% |
30 Jun, 18 | 19 | -13.64% | 3,723,565 | -20.70% | 23.80% | 1.42% | 10 | -54.55% | 6 | - |
31 Mar, 18 | 22 | - | 4,695,260 | - | 40.98% | - | 22 | - | - | - |
BioXcel Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of BioXcel Therapeutics's stock was made by Yocca Frank on Jun 18 2024, selling 372 shares at $1.28 per share (valued at $476.16).
BioXcel Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | 16 | 29 | 55.17% |
Q1 2024 | 12 | 10 | 120.00% |
Q4 2023 | 5 | 5 | 100.00% |
Q3 2023 | 5 | 5 | 100.00% |
Q2 2023 | 15 | 27 | 55.56% |
Q1 2023 | 22 | 27 | 81.48% |
Q4 2022 | 3 | 9 | 33.33% |
Q3 2022 | 1 | - | - |
Q2 2022 | 9 | 1 | 900.00% |
Q1 2022 | 10 | - | - |
Q4 2021 | - | 1 | - |
Q3 2021 | 2 | - | - |
Q2 2021 | 4 | 5 | 80.00% |
Q1 2021 | 11 | 29 | 37.93% |
Q4 2020 | 2 | 4 | 50.00% |
Q3 2020 | 3 | 5 | 60.00% |
Q2 2020 | 11 | 1 | 1100.00% |
Q1 2020 | 2 | 3 | 66.67% |
Q3 2019 | 8 | - | - |
Q2 2019 | 5 | 2 | 250.00% |
16 total buy trades, and 29 total sell trades (buy/sell ratio of 0.55%) were made by BioXcel Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | 19 | - |
Q1 2024 | - | - | - |
Q4 2023 | - | - | - |
Q3 2023 | - | - | - |
Q2 2023 | - | 9 | - |
Q1 2023 | - | 15 | - |
Q4 2022 | - | 4 | - |
Q3 2022 | - | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q4 2021 | - | - | - |
Q3 2021 | - | - | - |
Q2 2021 | - | 4 | - |
Q1 2021 | - | 24 | - |
Q4 2020 | - | 4 | - |
Q3 2020 | - | - | - |
Q2 2020 | - | - | - |
Q1 2020 | - | - | - |
Q3 2019 | 8 | - | - |
Q2 2019 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 19 open market sell trades of BioXcel Therapeutics's stocks.
BioXcel Therapeutics Peer Ownership
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
TGTX | TG Therapeutics, Inc. |
MREO | Mereo BioPharma Group plc |
APLS | Apellis Pharmaceuticals, Inc. |
EXEL | Exelixis, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
VKTX | Viking Therapeutics, Inc. |
INZY | Inozyme Pharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |
ELEV | Elevation Oncology, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |
BTAI Ownership FAQ
Who Owns BioXcel Therapeutics?
BioXcel Therapeutics is owned by institutional shareholders (31.63%), insiders (20.06%), and public (48.31%). The largest institutional shareholder of BioXcel Therapeutics is ARMISTICE CAPITAL, LLC (9.68% of total shares) and the top mutual fund owner is HARTFORD HLS SERIES FUND II INC (0.24% of total shares).
Who are the major institutional shareholders of BioXcel Therapeutics?
BioXcel Therapeutics's major institutional shareholders are ARMISTICE CAPITAL, LLC, FMR LLC, VANGUARD GROUP INC, BLACKROCK INC., and BNP PARIBAS ARBITRAGE, SNC. The top five shareholders own together 22.28% of the company's share outstanding.
How many BioXcel Therapeutics shareholders are there?
As of Jun 2024, there are 74 institutional shareholders of BioXcel Therapeutics.
What percentage of BioXcel Therapeutics is owned by ARMISTICE CAPITAL, LLC?
ARMISTICE CAPITAL, LLC owns 2.99M shares of BioXcel Therapeutics, representing 9.68% of the company's total shares outstanding, valued at $3.82M (as of Jun 2024).
What percentage of BioXcel Therapeutics is owned by FMR LLC?
As of Jun 2024, FMR LLC holds 2.21M shares of BioXcel Therapeutics (BTAI), compromising 7.14% of the company, valued at $2.82M.
What percentage of BioXcel Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC is the third largest holder of BioXcel Therapeutics. The company owns 970.43K of the company's shares outstanding (worth $1.24M).